Radio-pharmaceutical complexes
AssigneeAlgeta ASA
InventorsHanne Therese Bonge-Hansen, Olav Benjamin Ryan
Life of this patent
Estimating the term…
Abstract
A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor. Methods of treatment utilising such complexes and methods of formation of such complexes are provided.
Claims28
A tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor.
The complex as claimed in any preceding claim wherein the N-substituents on each of the four HOPO groups are each independently chosen from HO—, HOCH2—, HOCH2CH2—, HO—CH2CH2CH2—, HO—CH(CH3)CH2—, HO—CH2CH2CH2CH2—, HO—CH(CH3)CH2CH2—, HO—CH(CH2CH3)CH2—, HO—C(CH3)2CH2—, HO—CH(CH3)CH(CH3)— and HOCH2CH(CH2CH3)—.
A complex as claimed in any preceding claim wherein the tissue targeting moiety is a monoclonal or polyclonal antibody, an antibody fragment (such as Fab, F(ab′)2, Fab′ or scFv), or a construct of such antibodies and/or fragments.
A complex as claimed in any preceding claim wherein the tissue targeting moiety comprises at least one peptide chain having at least 90% sequence similarity with at least one of the following sequences:
- Light Chain:
- (Seq ID 1)
- DIQLTQSPSSLAVSAGENVTMSCKSSQSVLYSANHKNYLAWYQQKPGQS
- PKLLIYWASTRESGVPDRFTGSGSGTDFTLTISRVQVEDLAIYYCHQYL
- SSWTFGGGTKLEIKR
- (Seq ID 2)
- DIQLTQSPSSLASAAVEDRTMSCKSSQSVLYSANHKNYLAWYQQKPGQK
- AKLLIYWASTRESGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCHQYL
- SSWTFGGGTKLEIKR
- Heavy Chain:
- (Seq ID 3)
- QVQLQESGAELSKPGASVKMSCKASGYTFTSYWLHWIKQRPGQGLEWIG
- YINPRNDYTEYNQNFKDKATLTADKSSSTAYMQLSSLTSEDSAVYYCAR
- RDITTFYWGQGTTLTVSS
- (Seq ID 4)
- QVQLQQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIG
- YINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCAR
- RDITTFYWGQGTTVTVSS
- (Seq ID 5)
- QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYWLHWVRQAPGQGLEWIG
- YINPRNDYTEYNQNFKDKATITADESTNTAYMELSSLRSEDTAFYFCAR
- RDITTFYWGQGTTVTVSS
Use of a tissue targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor, in the manufacture of a medicament for the treatment of hyperplastic or neoplastic disease.
A method of treatment of a human or non-human animal (particularly one in need thereof) comprising administration of at least one tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group wherein the tissue targeting moiety has binding affinity for the CD22 receptor.
A pharmaceutical composition comprising a tissue-targeting complex comprising a tissue targeting moiety, an octadentate hydroxypyridinone-containing ligand comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group wherein the tissue targeting moiety has binding affinity for the CD22 receptor, together with at least one pharmaceutical carrier or excipient.
A method of formation of a tissue-targeting complex, said method comprising coupling a tissue targeting moiety to an octadentate hydroxypyridinone-containing ligand in aqueous solution, the complex comprising four HOPO moieties and the ion of an alpha-emitting thorium radionuclide, where at least one of the four HOPO moieties is substituted at the N-position with a hydroxyalkyl solubilising group and wherein the tissue targeting moiety has binding affinity for the CD22 receptor.
Dependencies are inferred from the claim text.